Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
James M. Cleary(Brigham and Women's Hospital), Julie-Aurore Losman(Brigham and Women's Hospital)
Cited by 77
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
|Cell|2021|586
Institutional implementation of clinical tumor profiling on an unselected cancer population
|JCI Insight|2016|447
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
|Journal for ImmunoTherapy of Cancer|2020|117